The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide
Open accessAbstract
The potential for proarrhythmic responses to the class IC sodium channel-blocking drugs encainide and flecainide has not been well described in young patients. Therefore, data were retrospectively collected from 36 institutions regarding 579 young patients who were administered encainide or flecainide for treatment of supraventricular tachycardias (encainide 86 patients, flecainide 369 patients) or ventricular arrhythmias (encainide 21 patients, flecainide 103 patients) to assess the frequency of proarrhythmia, cardiac arrest and death during therapy (adverse events). The two drugs were similar in regard to efficacy (flecainide 71.4%, encainide 59.8%) and rate of proarrhythmic responses (flecainide 7.4%; encainide 7.5%). However, patients receiving encainide more frequently experienced cardiac arrest (encainide 7.5% vs. flecainide 2.3%, p less than 0.05) or died during treatment (encainide 7.5% vs. flecainide 2.1%, p less than 0.05). Detailed data were provided for 44 patients experiencing one or more adverse events. Patient age, previous drug trials, concomitant therapy and days of inpatient monitoring were similar for patients receiving encainide or flecainide. However, echocardiographic left ventricular shortening before treatment was lower among patients receiving encainide (0.23 +/- 0.09) than among those receiving flecainide (0.34 +/- 0.06, p less than 0.05). Plasma drug concentrations were rarely elevated. Cardiac arrest (12 patients) and deaths (13 patients) occurred predominantly among patients with underlying heart disease, particularly among patients receiving flecainide for supraventricular tachycardia (8.3% vs. 0.3%, p less than 0.001). Fifteen patients with an ostensibly normal heart and normal ventricular function experienced proarrhythmia during treatment for supraventricular tachycardia, but only 3 of the 15 had a cardiac arrest or died. The relatively high incidence of adverse events should be considered when contemplating treatment with encainide or flecainide, particularly among patients with underlying heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Class Ic drugs such as encainide and flecainide are also proarrhythmic and should not be used in ACHD patients.370”
From European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE) (2017) · cites this paper as [370]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210629 · Cited by 3,289
Weir, M. (1990) · Cardiopulmonary Physical Therapy Journal · doi:10.1097/01823246-199001020-00009 · Cited by 1,061
Coplen, S. E., Antman, E. M., Berlin, J. A., Hewitt, P., & Chalmers, T. C. (1990) · Circulation · doi:10.1161/01.cir.82.4.1106 · Cited by 946
Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs.
Velebit, V., Podrid, P. J., Lown, B., Cohen, B. H., & Graboys, T. B. (1982) · Circulation · doi:10.1161/01.cir.65.5.886 · Cited by 629
Atrial flutter in the young: A collaborative study of 380 cases
Garson, A., Bink‐Boelkens, M. T. E., Hesslein, P. S., Hordof, A. J., Keane, J. F., Neches, W. H., & Porter, C.-B. J. (1985) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(85)80497-6 · Cited by 347
Anderson, J. L., Gilbert, E. M., Alpert, B. L., Henthorn, R. W., Waldo, A. L., Bhandari, A. K., Hawkinson, R. W., & Pritchett, E. L. C. (1989) · Circulation · doi:10.1161/01.cir.80.6.1557 · Cited by 287
Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram
Morganroth, J., & Horowitz, L. N. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90509-5 · Cited by 280
Oral Flecainide Acetate for the Treatment of Ventricular Arrhythmias
Anderson, J. L., Stewart, J. R., Perry, B. A., Hamersveld, D. D. V., Johnson, T. A., Conard, G. J., Chang, S. F., Kvam, D. C., & Pitt, B. (1981) · New England Journal of Medicine · doi:10.1056/nejm198108273050901 · Cited by 222
Malignant ventricular tachyarrhythmias associated with the use of encainide
Winkle, R. A., Mason, J. W., Griffin, J. C., & Ross, D. L. (1981) · American Heart Journal · doi:10.1016/0002-8703(81)90036-3 · Cited by 212
Gelder, I. C. V., Crijns, H. J. G. M., van Gilst, W. H., van Wijk, L. M., Hamer, H. P. M., & Lie, K. I. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90574-2 · Cited by 187
Cited by
Sorted by citations
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A. M., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 3,145
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., CHAITMAN, B. R., FROMER, M. A., Gregoratos, G., Klein, G. J., Myerburg, R. J., Quiñones, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.010 · Cited by 1,975
Al‐Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T. M., Field, M. E., Fonarow, G. C., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.054 · Cited by 1,902
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.178233 · Cited by 1,080
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.017 · Cited by 933
Metadata
- Authors
- Fish, F. A., Gillette, P. C., & Benson, D. W.
- Affiliations
- Northwestern University (US)
- Medical University of South Carolina (US)
- Corresponding author
- Fish, Frank A
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 1991-08
- Volume
- 18
- Issue
- 2
- Pages
- 356-365
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2084942160
- Cited by
- 193
- References
- 37
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 6 · 2022: 3 · 2021: 9 · 2020: 4 · 2019: 6 · 2018: 4 · 2017: 14 · 2016: 3 · 2015: 8 · 2014: 13 · 2013: 8 · 2012: 7
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- encainide, flecainide, class Ic antiarrhythmic drugs, drug-induced arrhythmia, cardiac arrest, drug-induced death, young patients, supraventricular tachycardia, ventricular arrhythmias, underlying heart disease, left ventricular shortening, adverse drug reactions, sodium channel blockers, plasma drug concentration, inpatient monitoring, drug safety and efficacy
- MeSH terms
- Anilides, Anti-Arrhythmia Agents, Arrhythmias, Cardiac, Child, Death, Sudden, Flecainide, Heart Arrest, Humans, Retrospective Studies, Risk Factors, Tachycardia, Tachycardia, Supraventricular, Incidence, Encainide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
